SEC Form EFFECT filed by Purple Biotech Ltd.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | July 30, 2024 4:05 P.M. |
Form: | F-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | July 30, 2024 4:05 P.M. |
Form: | F-1 | ||||||
|
REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation at the American Association for Cancer Research® (AACR) Special Conference on Advances in Pancreatic Cancer Research which will be held on September 15-18, 2024, in Boston, Massachusetts. Purple Biotech's poster titled, "Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer"
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced its executive management will participate in the H.C. Wainwright 26th Annual Global Investment Conference in a Fireside Chat presentation (virtual) and one-on-one meetings. The conference is being held on September 9-11, 2024, and the virtual Fireside Chat will be available on-demand starting on Monday, September 9 at 7:00 AM ET on the Investor section of Purple Biotech's website at www.purple-biotech.com for 30 days. Institu
Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of CM24+nivolumab and NAL-IRI/5FU/LV chemotherapy cohort Evaluating expansion of CM24 clinical program to a biomarker driven study in additional indications based on CEACAM1 novel oncology target on Neutrophil Extracellular Traps (NETs) in addition to enhancing immune response through the inhibition of CEACAM1 to CEACAM1 interactions Cash runway extended to Q3 2025 REHOVOT, Israel, Aug. 16, 2
6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from h
Seasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Lior Fhima, CPA, MBA, as Chief Financial Officer of the Company. Mr. Fhima brings deep expertise in financial management in the pharmaceutical industry and strong managerial capabilities. "We are honored to welcome Lior Fhima to the executive management team," said Gil Efron, Ch
HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.
Purple Biotech Ltd – ADR (NASDAQ:PPBT) shares are trading lower by 11.5% to $0.37 during Monday’s session after the company announced the exercise of warrants for $2 million gross proceeds. What Happened? Purple Biotech has entered into agreements for the exercise of existing warrants to purchase 5,633,509 American Depositary Shares (ADSs) at a reduced price of $0.36 per ADS, down from their original prices of $1.25 to $20.00 per ADS. This move involves warrants originally issued in October 2023, June 2020, January 2019, and June 2018. The offering, expected to close around July 2, is facilitated by H.C. Wainwright & Co. In return for the immediate exercise of these warrants, Purple
SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)
SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)
SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)